Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM5.02
|
Departure of Directors or Certain Officers; Election of |
On February 15, 2017, Tasos G. Konidaris was appointed to the
Board of Directors (the Board) of Kadmon Holdings, Inc. (the
Company), effective immediately. Mr. Konidaris has served as
Executive Vice President and Chief Financial Officer of Alcresta
Therapeutics, LLC (Alcresta) since March 2016. Prior to that, he
was Executive Vice President and Chief Financial Officer of
Ikaria, Inc., a biotherapeutics company, from October 2011 to May
2015. Prior to joining Ikaria, since 2007, Mr. Konidaris served
as Senior Vice President and Chief Financial Officer at Dun
Bradstreet Corporation (DB), a leading commercial information
services company. He was Principal Accounting Officer and led the
Global Finance Operations of DB beginning in 2005. From 2003 to
2005, Mr. Konidaris served as Group Vice President at
Schering-Plough Corporation, a pharmaceutical company. Earlier in
his career, Mr. Konidaris held senior financial and operational
positions of increasing responsibility at the Pharmacia
Corporation, Rhone-Poulenc Rorer, Novartis Corporation and
Bristol-Myers Squibb Company. Mr. Konidaris currently serves on
the boards of Alcresta, Pernix Therapeutics Holdings, Inc., and
Zep Inc. and has served on the board of Delcath Systems, Inc. Mr.
Konidaris holds an MBA from Drexel University, and a BS in
mathematics from Gwynedd Mercy College.
There are no family relationships between Mr. Konidaris and any
director or other executive officer of the Company nor are there
any transactions between Mr. Konidaris or any member of his
immediate family and the Company or any of its subsidiaries that
would be reportable as a related party transaction under the
rules of the United States Securities and Exchange Commission.
Further, there is no arrangement or understanding between Mr.
Konidaris and any other persons or entities to which Mr.
Konidaris was appointed as a director of the Company.
Upon his appointment to the Board, Mr. Konidaris became entitled
to the Company’s non-employee director compensation. As such,
Mr. Konidaris is entitled to receive $5,000 for each scheduled
Board meeting. Mr. Konidaris will also be entitled to receive
reimbursement of his reasonable travel expenses incurred in
connection with his attendance at Board and committee meetings.
In addition, non-employee directors of the Company are entitled
to receive an annual equity grant consisting of options to
purchase 25,000 shares of the Companys common stock under the
Companys 2016 Equity Incentive Plan.
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease. Kadmon Holdings, Inc. (NYSE:KDMN) Recent Trading Information
Kadmon Holdings, Inc. (NYSE:KDMN) closed its last trading session up +0.06 at 4.00 with 146,976 shares trading hands.